Christopher Shih, MD
Gastroenterology · Lancaster, PANPI 1881699445
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 268 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 33.3% of the total. 2025 is the largest year on record at $1,229, 2.2 times the $563 reported in 2019.
Across 268 payments — averaging $20.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Ardelyx, Inc.$439
- Takeda Pharmaceuticals U.S.A., Inc.$422
- Pfizer$421
- Bristol Myers Squibb$400
- Johnson & Johnson$327
- plus $2K from 19 others
Across 103 payments — averaging $2321.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$199K
- Boehringer Ingelheim International GmbH$40K
What the payments were for
- Food & beverage$5,595100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 102 | $1,870 |
| Ardelyx, Inc. | 8 | $439 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $422 |
| Pfizer | 22 | $421 |
| Bristol Myers Squibb | 23 | $400 |
| Johnson & Johnson | 14 | $327 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 12 | $264 |
| Sanofi | 10 | $254 |
| Regeneron Healthcare Solutions, Inc. | 10 | $246 |
| Mallinckrodt Hospital Products Inc. | 1 | $122 |
| E.r. Squibb & Sons, L.L.C. | 2 | $121 |
| Intercept Pharmaceuticals, Inc. | 7 | $116 |
| Gilead | 6 | $94 |
| Lilly USA, LLC | 4 | $92 |
| Amgen | 3 | $60 |
| Ironwood Pharmaceuticals, Inc | 4 | $54 |
| Madrigal Pharmaceuticals | 2 | $52 |
| QOL Medical, LLC | 2 | $51 |
| Shionogi Inc | 3 | $46 |
| Phathom Pharmaceuticals, Inc. | 3 | $40 |
| Novo Nordisk | 2 | $40 |
| Ferring Pharmaceuticals Inc. | 1 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Celltrion USA Inc. | 1 | $14 |
| Fresenius Kabi USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,610 in reported general payments places this provider in the 70th percentile of 935 gastroenterology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 93 | $69,056 |
| Mesalamine | 22 | $16,327 |
| MovantikNaloxegol Oxalate | 11 | $5,438 |
| Budesonide EcBudesonide | 24 | $5,400 |
| Dexlansoprazole DrDexlansoprazole | 12 | $4,174 |
| Budesonide DrBudesonide | 15 | $2,398 |
| Sucralfate | 16 | $2,214 |
| Pantoprazole Sodium | 149 | $2,071 |
| Ursodiol | 21 | $1,745 |
| Dicyclomine Hcl | 64 | $1,723 |
| Colestipol Hcl | 11 | $1,195 |
| Omeprazole | 85 | $936 |
| Rabeprazole Sodium | 23 | $865 |
| Esomeprazole Magnesium | 14 | $588 |
| Famotidine | 45 | $459 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $1,870 | $69,05693 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 935 gastroenterology providers in Pennsylvania.
Other gastroenterology in Lancaster
- John BetteridgeLancaster$310K
- Paul AllegrettiLancaster$73K
- Miguel RegueiroPittsburgh$1.5M
- Adam PeytonAllentown$985K
- Shahin RahimianWaynesboro$592K
- Sandra El-HachemPittsburgh$472K
- Harshit KharaDanville$438K
- Kofi ClarkeHershey$426K
- Michael KochmanPhiladelphia$361K
- Gary LichtensteinPhiladelphia$342K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.